NCT06427239View on ClinicalTrials.gov

Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 29, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions
Pancreatic Cancer
Interventions
DRUG

HRS-4642

HRS-4642 will be administrated per dose level in which the patients are assigned.

DRUG

Adebrelimab

Adebrelimab will be administrated per dose level in which the patients are assigned

Trial Locations (1)

200032

RECRUITING

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Fudan University

OTHER